KLRS Kalaris Therapeutics Inc
USHealthcareAs of 2026-07-10 16:00
Why KLRS matters now
Kalaris Therapeutics Inc (KLRS) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.44 with -1.11% on the session and $83.0M in market capitalization; recent performance reads 1-month +0.43% and YTD -44.08%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-10.9M, and EPS of $-0.46. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -55.6%.
The latest indexable market news headline is "Kalaris Appoints Laurie Keating to Board of Directors" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $18.00; recent insider activity includes PATTERSON LEONE D filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.63
P/S
0.00
EV/EBITDA
-1.25
DCF Value
$6.25
FCF Yield
-55.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-72.8%
ROA
-40.2%
ROIC
-46.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-10.9M | $-0.46 |
| Q4 2025 | $0.00 | $-10.0M | $-0.44 |
| FY 2025 | $0.00 | $-43.4M | $-2.85 |
| Q3 2025 | $0.00 | $-11.9M | $-0.64 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$18.25
Target (Median)
$18.00
Target Range
$14.00 - $23.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.14
Kalaris Therapeutics Inc. operates as a pharmaceutical enterprise. The company's core mission centers on developing innovative cell therapies. These treatments are designed to reactivate the body's inherent immunity against critical, virus-linked diseases, especially in patients with profoundly compromised immune systems.